CIA
CORT icon

Concurrent Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

Concurrent Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
13,380
+5,280
+65% +$319K 0.01% 934
2026
Q1 		$327K Sell
8,100
-5,745
-41% -$215K ﹤0.01% 1442
2025
Q4 		$482K Buy
13,845
+7,314
+112% +$574K 0.01% 1162
2025
Q3 		$543K Buy
6,531
+356
+6% +$25.8K 0.01% 883
2025
Q2 		$453K Buy
6,175
+205
+3% +$14.9K 0.01% 887
2025
Q1 		$682K Buy
+5,970
New +$363K 0.02% 653

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concurrent Investment Advisors's CORT Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Corcept Therapeutics (CORT) stake by 65% in Q2 2026, buying an estimated $319K and bringing the position to 13,380 shares worth $1.16M. The position accounts for 0.01% of the portfolio, ranked #934.

Concurrent Investment Advisors first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Concurrent Investment Advisors held 13,380 shares of Corcept Therapeutics worth $1.16M as of Q2 2026.
  • Concurrent Investment Advisors bought 5,280 Corcept Therapeutics shares in Q2 2026, an estimated $319K.
  • Corcept Therapeutics made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #934 holding.
  • Concurrent Investment Advisors first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.